The New Oncotype DX Breast Recurrence Score Report
The newly designed Breast Recurrence Score test report for your HR+, HER2-, early-stage, invasive breast cancer patients.
What Is the Test
The Oncotype DX test reveals the underlying tumour biology to help guide treatment decisions.
Prognostic vs. predictive
Only a truly predictive test can identify the right treatment for the right patient
Learn why it matters
TAILORx results eliminate uncertainty around intermediate scores and show that most patients do not benefit from chemotherapy
Get the results
Standard of Care
Only the Oncotype DX Breast Recurrence Score test is incorporated in the four major international guidelines and recommended by two major EU health technology assessment (HTA) bodies.
See the guidelines